½ÃÀ庸°í¼­
»óǰÄÚµå
1792427

´ÏÄÚÆ¾ ²­ ½ÃÀå º¸°í¼­ : À¯Çüº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°(2025-2033³â)

Nicotine Gum Market Report by Type, Application, Distribution Channel, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 141 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ´ÏÄÚÆ¾ ²­ ½ÃÀå ±Ô¸ð´Â 2024³â 17¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ 2025-2033³â 4%ÀÇ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2033³â¿¡´Â 25¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ¼¼°è ½ÃÀåÀÇ ¼ºÀå ¿äÀÎÀ¸·Î´Â ±Ý¿¬ ³ë·Â ¹× °Ç°­ ÀÇ½Ä Áõ°¡, Æí¸®ÇÑ OTC ´ÏÄÚÆ¾ ´ëü ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ´Ù¾çÇÑ °ÍµéÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦Ç°ÀÇ È¿À²¼ºÀ» ³ôÀÌ´Â ±â¼ú Çõ½Åµµ ½ÃÀå¿¡ Å« ºÎ°¡°¡Ä¡¸¦ ºÎ¿©Çϰí ÀÖ½À´Ï´Ù.

´ÏÄÚÆ¾ ²­ ½ÃÀå ºÐ¼® :

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ : Èí¿¬°ú °ü·ÃµÈ °Ç°­ À§Çè¿¡ ´ëÇÑ ÀÎ½Ä Áõ ¹× ¼¼°è ±Ý¿¬¿¡ ´ëÇÑ ´Ù¾çÇÑ ³ë·ÂÀÌ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
  • ÁÖ¿ä ½ÃÀå µ¿Çâ : ½ÃÆÇ(OTC) ´ÏÄÚÆ¾ ´ëü ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ±Ý¿¬À» ¸ñÇ¥·Î ÇÏ´Â »ç¶÷µé »çÀÌ¿¡¼­ Á¦Ç°ÀÇ ÆíÀǼº ¹× °¡¿ë¼ºÀÌ Çâ»óµÊ¿¡ µû¶ó ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
  • Áö¸®Àû µ¿Çâ : º¸°í¼­¿¡ µû¸£¸é ºÏ¹Ì´Â °Ç°­ ÁöÇâ ¼ÒºñÀÚ Áõ°¡·Î ½ÃÀå¿¡¼­ ÁÖµµÀûÀÎ ÁöÀ§¸¦ Â÷ÁöÇÕ´Ï´Ù.
  • °æÀï ±¸µµ : ÁÖ¿ä ±â¾÷Àº British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company µîÀÔ´Ï´Ù.
  • °úÁ¦ ¹× ±âȸ : °úÁ¦´Â ±Ý¿¬ º¸Á¶Á¦¿Í °ü·ÃµÈ »çȸÀû ½ºÆ¼±×¸¶¸¦ ±Øº¹ÇÏ°í ±Ý¿¬ °úÁ¤¿¡¼­ ´ÏÄÚÆ¾ ²­ÀÇ ¿ªÇÒ¿¡ ´ëÇØ ÀûÀýÇÑ ±³À°À» ÇØ¾ß ÇÕ´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, ´ÏÄÚÆ¾ ²­ ½ÃÀåÀÇ ÃÖ±Ù ºñÁî´Ï½º ±âȸ´Â Èí¿¬°ú °ü·ÃµÈ °Ç°­ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇÑ ±â¼úÀÇ ¹ßÀü°ú ±â¾÷ °£ÀÇ Çù¾÷À» Æ÷ÇÔÇÕ´Ï´Ù.

´ÏÄÚÆ¾ ²­ ½ÃÀå µ¿Çâ :

±Ý¿¬ Ȱµ¿ ¹× °Ç°­ ÀǽÄ

Èí¿¬À» ÁÙÀ̱â À§ÇÑ ¼¼°èÀÇ ³ë·ÂÀÌ °Ç°­ ÀÇ½Ä °íÁ¶¿Í ÇÔ²² ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Èí¿¬°ú °ü·ÃµÈ °Ç°­ À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â °¡¿îµ¥ »ç¶÷µéÀº ±Ý¿¬À» À§ÇÑ È¿°úÀûÀÎ Àü·«À» Àû±ØÀûÀ¸·Î ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ´ÏÄÚÆ¾ ²­Àº ´ÏÄÚÆ¾À» ¼­¼­È÷ ¹æÃâÇÏ¿© ±Ý´Ü Áõ»óÀ» Á¶ÀýÇÏ´Â ±Ý¿¬ º¸Á¶Á¦ÀÔ´Ï´Ù. ¶ÇÇÑ ÇコÄÉ¾î ±â°ü°ú ±ÔÁ¦ ´ç±¹ÀÇ ´Ù¾çÇÑ ±Ý¿¬ ÇÁ·Î±×·¥ÀÌ ´ÏÄÚÆ¾ ²­ ¼ö¿ä¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. °øÁß º¸°ÇÀÇ Á߿伺°ú ±Ý¿¬¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ³ë·ÂÀ¸·Î ±Ý¿¬ Ä¡·á¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÌ ²­ÀÌ ¹Þ¾Æµé¿©Áö°í ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. 2023³â 4¿ù 11ÀÏ, Neil O'Brien º¸°Ç»óÀº Policy Exchange¿¡¼­ Èí¿¬·ü °¨¼Ò ¹× ¹Ì¼º³âÀÚ VAPE ´ëó¿¡ °üÇÑ Á¤ºÎ °èȹ¿¡ ´ëÇØ ¿¬¼³À» ½Ç½ÃÇß½À´Ï´Ù.

OTC ´ÏÄÚÆ¾ ´ëü ¿ä¹ý ¼ö¿ä Áõ°¡

IMARC Group¿¡ µû¸£¸é 2023³â ¼¼°è OTC ÀǾàǰ »ê¾÷ ±Ô¸ð´Â 1,687¾ï ´Þ·¯¿´½À´Ï´Ù. ½ÃÀåÀ» ÃßÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â OTC ´ÏÄÚÆ¾ ġȯÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ²­Àº ó¹æÀü ¾øÀÌ ÀÚü Åõ¿©°¡ °¡´ÉÇÑ ½±°Ô ÀÔ¼ö °¡´ÉÇÑ OTC ¼Ö·ç¼ÇÀÔ´Ï´Ù. ÀÌ ²­ÀÌ ÀÇ·á µµ¿òÀ» ¿ä±¸ÇÏÁö ¾Ê°í ±Ý¿¬ÇÏ·Á´Â »ç¶÷µéÀÇ ÃÖ¼±ÀÇ ¼±ÅÃÀ¸·Î ÀαⰡ ÀÖ´Â °ÍÀº ±× ÀÔ¼öÀÇ ¿ëÀ̼º ¹× »ç¿ëÀÇ ¿ëÀ̼º ¶§¹®ÀÔ´Ï´Ù. »ç¶÷µéÀº ÇコÄɾ Àû±ØÀûÀ̾ú°í ´ÏÄÚÆ¾ ²­ ½ÃÀå Àü¸ÁÀº ¹à½À´Ï´Ù. °Ô´Ù°¡, 2024³â 1¿ù 24ÀÏ, ¿Àµð»þ ÁÖ Ä¿Å¹¿¡ ÀÖ´Â Sri Ram Chandra Bhanja(SCB) Dental College and Hospital¿¡¼­ ½Ç½ÃÇÑ ÀÓ»ó½ÃÇè¿¡¼­ Çൿ¿ä¹ý°ú Á¶ÇÕÇßÀ» °æ¿ìÀÇ ´ÏÄÚÆ¾ ġȯ ¿ä¹ý(NRT)ÀÇ ÇöÀúÇÑ À¯È¿¼ºÀÌ ¹ßÇ¥µÇ¾î, ±Ý¿¬ÀÇ ´ëó¿¡ Å« µ¹ÆÄ±¸°¡ ³ªÅ¸³µ½À´Ï´Ù.

±â¼ú Áøº¸ ¹× Á¦Ç° Çõ½Å

´ÏÄÚÆ¾ ´ëü ¿ä¹ýÀÇ Ã³¹æ ¹× Åõ¿©¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ±â¼ú °³¼±°ú Á¦Ç° Çõ½ÅÀº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ´ÏÄÚÆ¾ ²­ ±â¾÷Àº Á¦Ç°ÀÇ È¿À²¼º°ú »ç¿ëÀÚ °æÇèÀ» Çâ»ó½Ã۱â À§ÇØ ¿¬±¸°³¹ß(R&D) Ȱµ¿¿¡ ÀÚ±ÝÀ» ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Çâ»óµÈ ¸À°ú µ¶Æ¯ÇÑ Àü´Þ ½Ã½ºÅÛ°ú °°Àº Çõ½ÅÀ» ÅëÇØ »ç¿ëÀÚ´Â ÀÌ·¯ÇÑ ²­À» äÅÃÇß½À´Ï´Ù. °Ô´Ù°¡, ´ÏÄÚÆ¾ Áßµ¶°ú ±Ý´Ü Áõ»óÀÇ °úÁ¤¿¡ ´ëÇÑ ÀÌÇØ°¡ ±í¾îÁø °ÍÀº º¸´Ù È¿À²ÀûÀÎ ²­ Á¦ÇüÀ» ¸¸µå´Âµ¥ µµ¿òÀÌ µË´Ï´Ù. º¸´Ù È¿À²ÀûÀÎ ±Ý¿¬ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ´ÏÄÚÆ¾ ²­ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ÀÌ ½ÃÀåÀÇ ±â¾÷Àº °øÀÎ ´ç±¹À¸·ÎºÎÅÍ Á¦Ç° ½ÂÀÎÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Perrigo Company plc(PRGO)´Â 2023³â 5¿ù 16ÀÏ¿¡ ´ÏÄÚÆ¾ ÄÚÆÃµÈ ¹ÎÆ®·ÎÁ¨Áö 2mg ¹× 4mg OTCÀÇ ÃÖÁ¾ ½ÂÀÎÀ» ½Äǰ ÀǾ౹(FDA)À¸·ÎºÎÅÍ ÃëµæÇÏ¿´½À´Ï´Ù. ÀÌ Á¦Ç°Àº ±Ý¿¬À» ½ÃµµÇÏ´Â ¼ÒºñÀÚÀÇ ±Ý´Ü Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ´ÏÄݸ´ ÄÚÆÃ ¾ÆÀ̽º ¹ÎÆ®·ÎÁ¨Áö¿Í µ¿µîÇÑ Á¦Ç°À¸·Î ¼Ò¸ÅÁ¡ÀÇ ½ºÅä¾î ºê·£µå ¶óº§·Î ÆÇ¸ÅµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ´ÏÄÚÆ¾ ²­ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : À¯Çüº°

  • 2 Mg ´ÏÄÚÆ¾ ²­
  • 4 Mg ´ÏÄÚÆ¾ ²­
  • 6 Mg ´ÏÄÚÆ¾ ²­

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ÀÌÅ» Ŭ¸®´Ð
  • ÀÇ·á ÇàÀ§
  • °³ÀÎ Èí¿¬ÀÚ
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

  • ¼Ò¸Å ¾à±¹
  • Àü¹®Á¡
  • ¿Â¶óÀÎ ½ºÅä¾î
  • ±âŸ

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • British American Tobacco
    • Cambrex Corporation
    • GlaxoSmithKline
    • ITC Limited
    • Novartis
    • Johnson & Johnson Services
    • Perrigo
    • Pfizer
    • Takeda Pharmaceutical Company
AJY 25.08.27

The global nicotine gum market size reached USD 1.7 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4% during 2025-2033. There are various factors that are responsible for the growth of the global market, which include smoking cessation initiatives and heightened health awareness, rising demand for convenient over the counter (OTC) nicotine replacement therapies. Technological innovations for enhancing product efficacy also add significant value to the market.

Nicotine Gum Market Analysis:

  • Major Market Drivers: The increasing awareness about health risks associated with smoking, along with various smoking cessation initiatives worldwide, are acting as growth-inducing factors.
  • Key Market Trends: There is a rise in the demand for over the counter (OTC) nicotine replacement therapies. This, coupled with the enhanced convenience and accessibility of the product among individuals seeking to quit smoking, are supporting the market growth.
  • Geographical Trends: According to the report, North America enjoys a leading position in the market due to the rising number of health-conscious consumers.
  • Competitive Landscape: Top players in the nicotine gum industry are British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company, among many others.
  • Challenges and Opportunities: Challenges include the need to overcome social stigmas associated with smoking cessation aids and ensure proper education about the role of nicotine gum in the quitting process. Nonetheless, nicotine gum market recent opportunities are technological advancements and collaborations among companies to address smoking-related health issues.

Nicotine Gum Market Trends:

Smoking Cessation Initiatives and Health Awareness

Global efforts to reduce smoking, along with rising health awareness, are propelling the market expansion. People are actively looking for effective strategies to quit smoking as awareness about health risks connected with smoking increases among them. Nicotine gum is a smoking cessation aid that helps users manage the symptoms of withdrawal by releasing nicotine gradually and under control. In addition, various smoking cessation programs by healthcare organizations and regulatory authorities has created a favorable atmosphere for nicotine gum demand. The rising acceptance of this gum as an essential component of smoking cessation treatments due to the emphasis on public health and the ongoing efforts to eliminate smoking is impelling the market growth. On 11 April 2023, Neil O'Brien, Health Minister, delivered a speech at Policy Exchange on government plans to cut smoking rates and tackle underage vaping,

Growing Demand for OTC Nicotine Replacement Therapies

As per the IMARC Group, in 2023, the size of the OTC medication industry worldwide was US$ 168.7 Billion. One of the main factors propelling the market is the rising demand for OTC nicotine replacement medicines. This gum is an easily available OTC solution that enables users to self-administer therapy without a prescription. This gum's popularity as a top option for people trying to stop smoking without seeking medical help is due to its accessibility and ease of usage. People are becoming more proactive in managing their health, which is offering a positive nicotine gum market outlook. Furthermore, on 24 January 2024, in a significant breakthrough for tobacco cessation efforts, a clinical trial conducted at Sri Ram Chandra Bhanja (SCB) Dental College and Hospital in Cuttack, Odisha, unveiled the remarkable efficacy of nicotine replacement therapy (NRT) when combined with behavioral therapy.

Technological Advancements and Product Innovation

Continuous technological improvements and product innovations in the formulation and administration of nicotine replacement therapies are bolstering the market growth. Nicotine gum companies are spending money on research and development (R&D) activities to enhance the effectiveness of product as well as user experience. Users are adopting these gums owing to innovations like enhanced flavors and unique delivery systems. In addition, enhanced understanding of nicotine addiction and withdrawal processes are benefiting in the creation of gum formulations that are more efficient. The escalating demand for more efficient smoking cessation solutions is bolstering the nicotine gum market growth. Besides this, companies in the market are getting product approvals from the recognized authorities. For instance, Perrigo Company plc (PRGO) received final approval from the Food Drug Administration (FDA) for nicotine coated mint lozenges 2 mg and 4 mg OTC on 16 May 2023. The product helps in reducing withdrawal symptoms in consumers who are trying to quit smoking. Moreover, it will be marketed under retailer's store brand labels as a comparable offering to Nicorette coated ice mint lozenge.

Nicotine Gum Market Segmentation:

Breakup by Type:

  • 2 Mg Nicotine Gum
  • 4 Mg Nicotine Gum
  • 6 Mg Nicotine Gum

2 mg nicotine gum accounts for the majority of the market share

Those looking to cut back on their nicotine intake during their journey to quit smoking can find 2 mg category a suitable choice. 2mg nicotine gum is an ideal alternative for controlling withdrawal symptoms while progressively weaning off nicotine dependence, making it the perfect choice among light to moderate smokers. Furthermore, it is advised for people who need a step-down strategy and in the early phases of quitting in order to enable a more regulated shift to a life free of nicotine.

Breakup by Application:

  • Withdrawal Clinics
  • Medical Practice
  • Individual Smokers
  • Others

Medical practice holds the largest share of the industry

Nicotine gums are used in more comprehensive smoking cessation programs in medical settings. Physicians may recommend this gum to patients as part of individualized smoking cessation regimens or during routine consultations. The progressive and regulated release of nicotine from the gum is consistent with evidence-based therapies. In the medical practice application, the importance of healthcare professionals in helping people quit is emphasized, along with the health advantages and individualized assistance that come with using nicotine gum.

Breakup by Distribution Channel:

  • Retail Pharmacies
  • Specialty Stores
  • Online Stores
  • Others

Retail pharmacies represent the leading market segment

Nicotine gums are readily available at retail pharmacies. Consumers in search of smoking cessation products can easily locate them in close proximity to their homes. This gum is easily available and pharmacists can offer their advice related to medication, which makes it a favored option for those seeking person-to-person support and quick access to quit smoking products.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest nicotine gum market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for nicotine gum.

North America stands as a significant market due to robust smoking cessation efforts, heightened health awareness, and a substantial consumer base. The region has a well-established healthcare infrastructure and proactive regulatory measures that contribute to the popularity of these gums as a preferred smoking cessation aid. In addition, there is an increase in the number of individuals seeking effective solutions to quit smoking in the North America region. Besides this, the wide availability of these gum across various distribution channels including retail pharmacies and online stores, assists in increasing nicotine gum market revenue. On 18 March 2024, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the completion of a 5-year, US$ 100-Million-dollar investment strategy, one year ahead of schedule. The project adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, which will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the nicotine gum industry include British American Tobacco, Cambrex Corporation, GlaxoSmithKline, ITC Limited, Johnson & Johnson Services, Novartis, Perrigo, Pfizer, Takeda Pharmaceutical Company.
  • Key players in the market are engaging in strategic initiatives that are focused on product innovation, marketing, and collaborative efforts. Continuous R&D investments by key manufacturers aim to enhance the effectiveness and appeal of the product formulations. These companies leverage technological advancements to create novel delivery mechanisms, improved flavors, and better taste masking, meeting consumer preferences and driving market growth. Moreover, robust marketing campaigns and partnerships with healthcare organizations contribute to the rising awareness about smoking cessation benefits among individuals while expanding the consumer base. Collaborative efforts between industry stakeholders and regulatory bodies ensure compliance with health standards and foster a positive market environment. On 3 July 2023, Haleon, the world's biggest standalone consumer health business, explored the sale of its nicotine gum business as it aims to streamline its business. The company is working with an adviser to find potential suitors for its Nicotinell brand of nicotine gum, which could be worth about US$ 800 Million in sales.

Key Questions Answered in This Report

  • 1.What was the value of the global nicotine gum market in 2024?
  • 2.At what CAGR is the nicotine gum market projected to grow over the forecast period 2025-2033?
  • 3.What are the key factors driving the nicotine gum market?
  • 4.Which is the leading segment based on type in the nicotine gum market?
  • 5.Which region accounts for the largest nicotine gum market share?
  • 6.Which are the leading companies in the global nicotine gum market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Nicotine Gum Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 2 Mg Nicotine Gum
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 4 Mg Nicotine Gum
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 6 Mg Nicotine Gum
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Withdrawal Clinics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Medical Practice
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Individual Smokers
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Retail Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 British American Tobacco
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Cambrex Corporation
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 GlaxoSmithKline
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 ITC Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Novartis
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Johnson & Johnson Services
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Perrigo
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦